These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 20107315

  • 21. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality.
    Van Linden AA, Baturin D, Ford JB, Fosmire SP, Gardner L, Korch C, Reigan P, Porter CC.
    Mol Cancer Ther; 2013 Dec; 12(12):2675-84. PubMed ID: 24121103
    [Abstract] [Full Text] [Related]

  • 22. Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy.
    Clausse V, Goloudina AR, Uyanik B, Kochetkova EY, Richaud S, Fedorova OA, Hammann A, Bardou M, Barlev NA, Garrido C, Demidov ON.
    Cell Death Dis; 2016 Apr 14; 7(4):e2195. PubMed ID: 27077811
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells.
    Qi W, Xie C, Li C, Caldwell JT, Edwards H, Taub JW, Wang Y, Lin H, Ge Y.
    J Hematol Oncol; 2014 Aug 01; 7():53. PubMed ID: 25084614
    [Abstract] [Full Text] [Related]

  • 25. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.
    Carrassa L, Chilà R, Lupi M, Ricci F, Celenza C, Mazzoletti M, Broggini M, Damia G.
    Cell Cycle; 2012 Jul 01; 11(13):2507-17. PubMed ID: 22713237
    [Abstract] [Full Text] [Related]

  • 26. Antitumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer.
    Murakami K, Kita Y, Sakatani T, Hamada A, Mizuno K, Nakamura K, Takada H, Matsumoto K, Sano T, Goto T, Akamatsu S, Saito R, Tsuruyama T, Ogawa O, Kobayashi T.
    Cancer Sci; 2021 Sep 01; 112(9):3669-3681. PubMed ID: 34212455
    [Abstract] [Full Text] [Related]

  • 27. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
    Chilà R, Basana A, Lupi M, Guffanti F, Gaudio E, Rinaldi A, Cascione L, Restelli V, Tarantelli C, Bertoni F, Damia G, Carrassa L.
    Oncotarget; 2015 Feb 20; 6(5):3394-408. PubMed ID: 25428911
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
    Liu L, Qiu S, Liu Y, Liu Z, Zheng Y, Su X, Chen B, Chen H.
    Neoplasma; 2016 Feb 20; 63(2):193-200. PubMed ID: 26774139
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.
    Beeharry N, Banina E, Hittle J, Skobeleva N, Khazak V, Deacon S, Andrake M, Egleston BL, Peterson JR, Astsaturov I, Yen TJ.
    Cell Cycle; 2014 Feb 20; 13(14):2172-91. PubMed ID: 24955955
    [Abstract] [Full Text] [Related]

  • 34. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
    Tanaka N, Patel AA, Wang J, Frederick MJ, Kalu NN, Zhao M, Fitzgerald AL, Xie TX, Silver NL, Caulin C, Zhou G, Skinner HD, Johnson FM, Myers JN, Osman AA.
    Clin Cancer Res; 2015 Nov 01; 21(21):4831-44. PubMed ID: 26124202
    [Abstract] [Full Text] [Related]

  • 35. Wee1 kinase as a target for cancer therapy.
    Do K, Doroshow JH, Kummar S.
    Cell Cycle; 2013 Oct 01; 12(19):3159-64. PubMed ID: 24013427
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.
    Aarts M, Sharpe R, Garcia-Murillas I, Gevensleben H, Hurd MS, Shumway SD, Toniatti C, Ashworth A, Turner NC.
    Cancer Discov; 2012 Jun 01; 2(6):524-39. PubMed ID: 22628408
    [Abstract] [Full Text] [Related]

  • 38. WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner.
    Lal S, Zarei M, Chand SN, Dylgjeri E, Mambelli-Lisboa NC, Pishvaian MJ, Yeo CJ, Winter JM, Brody JR.
    Sci Rep; 2016 Sep 12; 6():33323. PubMed ID: 27616351
    [Abstract] [Full Text] [Related]

  • 39. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
    Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, Kotani H.
    Mol Cancer Ther; 2010 Jul 12; 9(7):1956-67. PubMed ID: 20571069
    [Abstract] [Full Text] [Related]

  • 40. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines.
    Barbosa RSS, Dantonio PM, Guimarães T, de Oliveira MB, Fook Alves VL, Sandes AF, Fernando RC, Colleoni GWB.
    Biochem Biophys Res Commun; 2019 Nov 12; 519(3):597-604. PubMed ID: 31540690
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.